

























Compound No.	Structure and/or Name
1	 carboplatin
2	 cisplatin
3	 paclitaxel
4	 docetaxel
5	pegylated liposomal doxorubicin
6	 doxorubicin

Compound No.	Structure and/or Name
7	 gemcitabine
8	 cytarabine (AraC)
9	 fludarabine
10	 5-FU (Fluorouracil)
11	 irinotecan

Compound No.	Structure and/or Name
12	 topotecan
13	 temozolomide
14	 triapine
15	 5-azacytidine
16	 capecitabine

Compound No.	Structure and/or Name
17	AraC-FdUMP[10] (CF-10)
18	 cladribine
19	 decitabine
20	 hydroxyurea
21	 oxaliplatin

Compound No.	Structure and/or Name
22	 olaparib
23	 niraparib
24	 rucaparib
25	 talazoparib
26	 veliparib
27	 pamiparib










Compound No.	Structure and/or Name
28	 iniparib
29	 E7016
30	 CEP-9722

Figure 3

Compound No.	Structure and/or Name
31	nivolumab
32	pembrolizumab
33	cemiplimab
34	spartalizumab
35	ABBV-181 (an anti-PD1 monoclonal antibody)
36	lodapolimab
37	zimberelimab
38	toripalimab (Tuoyi)
39	tislelizumab
40	camrelizumab
41	sintilimab (Tyvyt)
42	Genolimzumab (GB226)
43	AK105 (a humanized monoclonal antibody)
44	HLX-10 (monoclonal antibody)
45	AK103
46	BAT-1306
47	GSL-010
48	CS1003 (humanized anti-PD-1 IgG4 monoclonal antibody)
49	LZM009
50	SCT-I10A (monoclonal antibody)

Figure 4

Compound No.	Structure and/or Name
51	Atezolizumab
52	Avelumab
53	Durvalumab
54	KN035 (fusion protein)
55	CS1001 (monoclonal antibody)
56	SHR-1316 (fully humanized monoclonal antibody)
57	TQB2450 (humanized monoclonal antibody)
58	BGB-A333 (humanized IgG1-variant monoclonal antibody)
59	KL-A167
60	KN046 (recombinant humanized antibody)
61	MSB2311 (humanized monoclonal antibody)
62	HLX-20 (monoclonal antibody)

Compound No.	Structure
1A	
2A	
3A	
4A	
5A	
6A	









Compound No.	Structure
7A	
8A	
9A	
10A	
11A	
12A	

Figure 6




Studies of a Compound (1A) and Talazoparib alone or in combination in TOV112D cell line

Figure 7




Studies of a Compound (1A) and Niraparib alone or in combination in MDA-MB-436 cell line

Figure 8




Studies of a Compound (1A) and Carboplatin alone or in combination in TOV21G xenograft model

Figure 9




Studies of a Compound (1A) and gemcitabine alone or in combination in SJSA-1 xenograft model

Figure 10




Studies of a Compound (1A) and Talazoparib alone or in combination in OVCAR3 xenograft model

Figure 11



Studies of a Compound (1A) and an Anti-PD1 alone or in combination in MC38 syngeneic tumor model

Figure 12



Studies of a Compound (1A) and an Anti-PD1 alone or in combination in MC38 syngenic tumor model






Figure 14




Compound (1A) in a H1755 NSCLC tumor model




Compound (1A) in a SKUT-1 uterine leiomyosarcoma tumor model

Figure 16



Compound (1A) in an OVCAR3 ovarian tumor model

Figure 17



Compound (1A) in a x2 MDA-MB-468 TNBC tumor model

Figure 18




Figure 19




Figure 20





Figure 21






Figure 22

Figure 23




Figure 24




Figure 25




Figure 26




Figure 27





Figure 28



Compound (1A) in combination with Doxorubicin in OVCAR3 ovarian tumor model